For research use only. Not for therapeutic Use.
Tadnersen (BIIB078), an antisense oligonucleotide (ASO), selectively targets C9ORF72 transcript variants 1 and 3 that carry the expansion[1].
Tadnersen (BIIB078) is an RNAse H oligomer that selectively inhibits mutant C9ORF72 transcripts. Tadnersen is used for the research of Amyotrophic Lateral Sclerosis (ALS)[2].
| Catalog Number | I045374 |
| CAS Number | 2170507-65-8 |
| Purity | ≥95% |
| Reference | [1]. Smeyers J, et al. C9ORF72: What It Is, What It Does, and Why It Matters. Front Cell Neurosci. 2021;15:661447. Published 2021 May 5. [2]. Aoki Y, et al. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases [published online ahead of print, 2021 Jun 3]. J Neuromuscul Dis. 2021;10.3233/JND-200560. |
